Alzheimer’s drug shows promise for Huntington’s disease
Dimebon (latrepirdine), a pill being developed for Alzheimer’s disease, has been found to improve mental abilities in some patients with Huntington’s disease, says a new study.
The research has been published in the Archives of Neurology.
“This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease,” said University of Rochester Medical Center neurologist Karl Kieburtz, M.D., the lead author of the study. “While more investigation needs to be done, these results are encouraging and show, for the first time, a statistically significant benefit in terms of improved cognitive function in patients with Huntington’s disease.”
Huntington’s disease is a progressive neurodegenerative disorder that impacts movement, behavior, cognition, and generally results in death within 20 years of the disease’s onset. The disease steadily erodes a person’s memory and their ability to think and learn. Over time, this cognitive impairment contributes to the loss of the ability to work and perform the activities of daily life. There are no treatments current available that effectively alter the course of the disease or improve cognition.
It is believed that mitochondria – the part of the cell that helps convert food to energy – plays a role in the development of Huntington’s disease. Lampridine stabilizes and enhances mitochondrial function, a result that has been shown to improve behavioral, cognitive, and functional outcomes in Alzheimer’s disease. Scientists speculate that this may have the same effect in patients with Huntington’s disease.
The investigators studied the impact of the drug on 91 patients over a 90 day period. (ANI)
Related Posts
Other cognitive skills decline prior to memory in Alzheimer’s patients
Washington, Oct 13 (ANI): People, who go on to have Alzheimer's disease (AD), lose many cognitive abilities, much before they actually succumb to dementia caused by the neurodegenerative disorder, a new study has revealed.
Researchers at the University... |
Higher urate levels slow the progression of Parskinson’s disease
Washington, Oct 13 (ANI): Parkinson's patients, who have higher levels of urate, a chemical that at very high level is associated with gout, have slow progression of the neuro-degenerative disease, a new study has found.
Although it is not known if the... |
Healthy people with brain plaques at increased Alzheimer’s risk
Washington, Dec 15 (ANI): Healthy people who have an abnormal build-up of a protein in the brain linked with Alzheimer's have a higher risk of developing the disease, two new studies have found.
Scientists have long assumed that amyloid brain... |
Diabetics with Alzheimer’s have ’slower memory loss rate’
Washington, Oct 28 (ANI): People who have both Alzheimer's disease (AD) and diabetes have a slower rate of memory loss than people who suffer only from AD, says a new study.
Earlier research has shown that diabetes increases the risk of Alzheimer's disease... |
Reduced muscle strength linked to Alzheimer’s risk
Washington, Nov 10 (ANI): People with weaker muscles are at an increased risk of developing Alzheimer's disease, claims a new study.
The study has been published in the November issue of Archives of Neurology, one of the JAMA/Archives journals.
Alzheimer's... |
Smoking for many years may reduce Parkinson’s disease risk
Smoking for a greater number of years may reduce the risk of Parkinson's disease, but smoking a larger number of cigarettes per day may not cut the risk, says a new study.
The study has been published in the March 10, 2010, online issue of Neurology,... |
